

Noble Life Sciences Newsletter - May 2013



301-861-0009

www.noblelifesci.com

MORE THAN A CRO – YOUR PRECLINICAL DRUG DEVELOPMENT PARTNER

CELL & ANIMAL DISEASE MODELS * PROTEIN PRODUCTION * TUMOR PROFILING * VIVARIUM SERVICES

Welcome to Noble's Newsletter. In this Issue...

We spotlight two newly expanded capabilities to expedite your preclinical studies:

- [Continuous drug infusion](#) with implantable osmotic pumps
- [Bio-luminescent imaging](#) to visualize therapeutic effects

Continuous Drug Infusion in Preclinical Development

Noble offers implantable osmotic pumps for continuous drug infusion into mice or rats as an alternative to repeated bolus injections of a target compound. Continuous infusion may be a superior approach when fluctuating plasma drug levels make study results difficult to interpret or even useless. Implantable pumps minimize the chance of animal interference and infection, allow unrestrained movement, and can reduce the stress to animals from repeated injections and connections to external infusion pumps.

Applications for continuous infusion with implantable osmotic pumps:

- Deliver a therapeutic agent with poor bioavailability, fast clearance rate, or a narrow therapeutic index
- Establish pharmacokinetic parameters
- Compare the efficacy of injection versus continuous infusion
- Deliver drugs directly to a tumor when used with a catheter
- Determine carcinogenicity or measure therapeutic drug efficacy in tumors
- Enhance bio-luminescent imaging studies via continuous delivery of bio-luminescent substrates
- Deliver substances directly to the brain, bypassing the blood-brain barrier

[Learn More](#)

Molecular Imaging Capabilities

Noble now offers:

- A biophotonic imaging system for whole body, real-time in vivo imaging using bioluminescence or fluorescence
- C-arm imaging scanner intensifier with radiographic capabilities

[Learn More](#)

About Noble Life Sciences

Our continuum of preclinical research services includes a best-in-class vivarium, cell and animal disease models, preclinical protein and monoclonal antibody production, and biomarker selection and validation process.

Meet Noble's VP of Translational Research Dr. Jeffrey Strovel

Prior to joining Noble, Jeff was the Head of Discovery Research at Avalon Pharmaceuticals where he played a critical role in developing the company's novel biomarker-driven discovery systems. He has also led programs for small molecule drug discovery and development including drug target discovery, Hit to Lead, Drug lead optimization, *in vitro* and pharmacodynamic biomarker discovery. Earlier in his career, Jeff held positions at the University of Maryland and the National Cancer Institute. Jeff's major focus at Noble is helping clients create and manage their oncology drug development programs.

Meet us at:

Steve Horrigan our CSO and Jeff Strovel are available for discussions on your preclinical development needs at the Predictive Models in Oncology Meeting in Philadelphia, June 3-5. Contact us to set up a meeting info@noblelifesci.com.

Ask About Our Total Program Management

Leverage our years of successful drug development experience and strong scientific expertise to help design your drug development strategy and implement the total preclinical development program.

For more information visit www.noblelifesci.com or e-mail us at tng@noblelifesci.com